Gilde Healthcare Amends CVRx Stake, Signals Ownership Update

TL;DR

**Gilde Healthcare just updated its CVRx stake, watch for potential market reaction.**

AI Summary

Gilde Healthcare IV U.A. filed an Amendment No. 2 to its Schedule 13D for CVRx, Inc. on January 17, 2024. This filing updates their beneficial ownership of CVRx, Inc.'s Common Stock, par value $0.01 per share, indicating a change in their holdings or their intent regarding the company. For investors, this matters because Gilde Healthcare is a significant institutional holder, and changes in their position can signal their confidence (or lack thereof) in CVRx's future performance, potentially influencing stock price.

Why It Matters

This filing indicates a change in a major institutional investor's position or intent regarding CVRx, Inc., which can influence market perception and stock valuation.

Risk Assessment

Risk Level: medium — Changes in significant institutional ownership can introduce volatility and uncertainty for a stock.

Analyst Insight

Investors should monitor subsequent filings from Gilde Healthcare IV U.A. to understand the specific nature of the change in their CVRx, Inc. holdings and consider how this might align with their own investment thesis.

Key Players & Entities

• Gilde Healthcare IV U.A. (company) — the reporting person filing the SC 13D/A
• CVRx, Inc. (company) — the subject company whose securities are being reported
• Edwin de Graaf (person) — person authorized to receive notices for Gilde Healthcare IV U.A.
• $0.01 (dollar_amount) — par value per share of CVRx, Inc. Common Stock
• January 17, 2024 (date) — date of event requiring the filing of this statement

FAQ

Key Financial Figures

• $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o

Filing Documents

• d736880dsc13da.htm (SC 13D/A) — 114KB
• 0001193125-24-010855.txt ( ) — 116KB

Security and Issuer

Item 1. Security and Issuer. There are no changes to the Item 1 information previously filed.

Identity and Background

Item 2. Identity and Background. There are no changes to the Item 2 information previously filed.

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration. There are no changes to the Item 3 information previously filed.

Purpose of Transaction

Item 4. Purpose of Transaction.

is hereby

Item 4 is hereby amended and supplemented by adding the following: Between December 29, 2023 and January 18, 2024, Gilde Healthcare sold an aggregate of 230,557 shares of Common Stock of the Company in open market transactions.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

is hereby amended and restated in its entirety below

Item 5 is hereby amended and restated in its entirety below: (a) According to the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on October 31, 2023, there were 20,815,635 shares of Common Stock outstanding as of October 24, 2023. Gilde Healthcare is the record holder of an aggregate of 1,365,743 shares of Common Stock and 2,463 options to purchase Common Stock exercisable within 60 days of January 17, 2024, which together represents beneficial ownership of approximately 6.6% of the outstanding shares of Common Stock. GHCIVM, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare. As a result, each of the Reporting Persons may beneficially own an aggregate of 1,368,206 shares of Common Stock, or approximately 6.6% of the outstanding Common Stock. (b) Each Reporting Person has shared power to vote and dispose of 1,368,206 shares of Common Stock. (c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuers securities within the past 60 days. (d) Only Gilde Healthcare has the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by Gilde Healthcare. (e) Not applicable. CUSIP NO . 126638105 13D Page 7 of 9 Pages

Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer. Except as referenced herein, there are no changes to the Item 6 information previously filed.

Materials to be Filed as Exhibits

Item 7. Materials to be Filed as Exhibits. There are no changes to the Item 7 information previously filed. CUSIP NO . 126638105 13D Page 8 of 9 Pages

Signatures

Signatures After reasonable inquiry and to the best knowledge and belief of the undersigned, such person certifies that the information set forth in this Statement with respect to such person is true, complete and correct. Dated: January 19, 2024 COOPERATIEVE GILDE HEALTHCARE IV U.A. By: GILDE HEALTHCARE IV MANAGEMENT BV Its: Manager By: /s/ Edwin de Graaf Name: Edwin de Graaf Title: Managing Director GILDE HEALTHCARE IV MANAGEMENT BV By: /s/ Edwin de Graaf Name: Edwin de Graaf Title: Managing Director GILDE HEALTHCARE HOLDING BV By: /s/ Edwin de Graaf Name: Edwin de Graaf Title: Managing Director MANAPOURI B.V. By: /s/ Edwin de Graaf Name: Edwin de Graaf Title: Managing Partner MARTEMANSHURK B.V. By: /s/ Pieter van der Meer Name: Pieter van der Meer Title: Managing Partner Annex A 60 Day Trading History The following transactions were effected by Cooperatieve Gilde Healthcare IV U.A. in Common Stock during the past 60 days: Trade Date Amount Sold Weighted Average Price Per Share 12/21/2023 18,386 $ 25.213 12/22/2023 7,423 $ 25.171 12/26/2023 124,191 $ 29.362 12/27/2023 35,000 $ 30.594 12/28/2023 47,722 $ 32.221 12/29/2023 17,278 $ 31.734 01/02/2024 33,154 $ 30.723 01/03/2024 2,114 $ 30.052 01/04/2024 19,394 $ 29.740 01/05/2024 12,876 $ 29.359 01/08/2024 19,322 $ 28.411 01/09/2024 25,269 $ 28.340 01/10/2024 37,871 $ 28.208 01/11/2024 10,000 $ 28.133 01/12/2024 4,746 $ 28.130 01/16/2024 4,944 $ 28.025 01/17/2024 30,310 $ 27.561 01/18/2024 13,279 $ 27.401

View Full Filing

View this SC 13D/A filing on SEC EDGAR